nemu

  1. HOME
  2. Portfolio

Portfolio

Deep pipeline of novel compounds, each with the potential to be first or best-in-class treatments for unmet patient needs

AskAt’s strategy centers on utilizing this global, integrated collaboration network to continually add value to each of its candidate programs.

Outlicensed Programs

Program Indication Discovery &
Pre-clinical
Clinical Registration Marketed Development
Region
Partner
Phase 1 Phase 2 Phase 3
Program Indication Phase Development
Region
Partner
AAT-007 EP4 antagonist Cancer
P1 On-going US Ikena
Oncology
On-going
P1 On-going China NewBay
Chronic Pain
Completed
P1 Completed China Haihe
Chronic Pain
(Dog)
Launched US Elanco
Launched EU and UK Elanco
Approved Japan
and Brazil
Elanco
AAT-008 EP4 antagonist Cancer
P1 ready
P1 ready US Ikena
Oncology
P1 ready
P1 ready China NewBay
Chronic Pain
(Dog)
On-going
Discovery &
Pre-clinical
On-going
US, EU,
and UK
Elanco
AAT-076 COX-2 inhibitor Neuropathic Pain
On-going
P1 On-going China Haihe
AAT-730 CB2 agonist IBS1, IBD2, Neuropathic Pain
On-going
Discovery &
Pre-clinical
On-going
US OCT*

* Oxford Cannabinoid Technologies

Inhouse Development or Buisiness Development Programs

Program Indication Discovery &
Pre-clinical
Clinical Registration Marketed Development
Region
Partner
Phase 1 Phase 2 Phase 3
Program Indication Phase Development
Region
Partner
AAT-009 C5-HT4 partial agonist Dementia
P2 Ready
P2 Ready US
AAT-076 COX-2 inhibitor Acute Pain
P2 Ready
P2 Ready US
Neuropathic Pain
P1 ready
P1 ready Japan
AAT-730 CB2 agonist All potential
indications
On-going
Discovery &
Pre-clinical
On-going
Japan

AskAt's license

Program Indication/
Route/
Others
Partners Territory R&D Stage
AAT-007 Cancer and all other human diseases (oral) Ikena Oncology Worldwide except China and Taiwan Clinical
NewBay China Clinical
Pain Haihe China Clinical
Topical license
opportunity
available
Worldwide Pre-clinical
Animal Health Aratana/Elanco Worldwide Marketed (Dog)
AAT-008 Cancer and all other human diseases (oral) Ikena Oncology Worldwide except China and Taiwan Pre-clinical
NewBay China Pre-clinical
Pain license
opportunity
available
China Pre-clinical
Animal Health Aratana Worldwide Pre-clinical
Autoimmune
Disease
license
opportunity
available
China Pre-clinical
Topical license
opportunity
available
Pre-clinical
AAT-009 Dementia license
opportunity
available
Worldwide Clinical
AAT-076 Cancer license
opportunity
available
Worldwide Clinical
Pain Haihe China Clinical
license
opportunity
available
Worldwide
except
China
Clinical
All potential
indications
except
Cancer and Pain
license
opportunity
available
Worldwide Pre-clinical/
clinical
AAT-730 All potential
indications
OCT Worldwide
except
Japan
Pre-clinical
license
opportunity
available
Japan Discovery

PAGE TOP

Menu